Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial - The Lancet Oncology
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma | NEJM
CheckMate-067: 6.5-Year Follow-up Shows Durable Benefit With Nivolumab-Containing Regimen in Advanced Melanoma
CheckMate-067: 6.5-Year Follow-up Shows Durable Benefit With Nivolumab-Containing Regimen in Advanced Melanoma
Checkmate 067 and 238 Melanoma Efficacy | OPDIVO® (nivolumab), OPDIVO + YERVOY® (ipilimumab)
a) Progression-free survival (PFS) and (b) overall survival (OS). CI,... | Download Scientific Diagram
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma | NEJM
Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada | SpringerLink
Six-and-a-Half-Year Outcomes for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Continue to Demonstrate Durable Long-Term Survival Benefits in Patients with Advanced Melanoma - AIM at Melanoma Foundation
The Lancet Oncology on Twitter: "Presented at #ESMO2018 @myESMO: #Nivolumab plus #ipilimumab or nivolumab alone versus ipilimumab alone in advanced #melanoma (#CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
Perspective on the Use of Nivolumab Combined with Ipilimumab For Advanced Melanoma | SCF - Skin Cancer Foundation Provider
Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study - ScienceDirect
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma | NEJM
Figure 5 | Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma | NEJM
Time to next treatment or death as a candidate surrogate endpoint for overall survival in advanced melanoma patients treated with immune checkpoint inhibitors: an insight from the phase III CheckMate 067 trial -
References in Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial - The Lancet Oncology
Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials - The Lancet Oncology
Clinical utility of nivolumab in the treatment of advanced melanoma | TCRM
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial - The Lancet Oncology
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma | NEJM
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma | NEJM
